Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (191-200 of 539) with videos related to

Pageof 54
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2005
Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTLCarina Lotz, Sarah Abdel Mutallib, Nicole Oehlrich, et al.
Cytometry. Part B, Clinical Cytometry|December 16, 2015
Potential therapeutic targets in plasma cell disorders: A flow cytometry studyKatharina Lisenko, Stefan Schönland, Ute Hegenbart, et al.
Cancers|July 24, 2021
Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationEva-Maria Klein, Sandra Sauer, Sabrina Klein, et al.
Transplantation and Cellular Therapy|July 2, 2021
Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma PatientsSandra Sauer, Katharina Erdmann, Alexandra D Jensen, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trialThomas Schmitt, Hartmut Goldschmidt, Kai Neben, et al.
Oncoimmunology|July 29, 2016
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitroIsabelle Krämer, Melanie Engelhardt, Sabrina Fichtner, et al.
Haematologica|October 17, 2009
Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myelomaJo Caers, Dirk Hose, Ine Kuipers, et al.
Haematologica|July 28, 2011
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patientsSophie L Corthals, Rowan Kuiper, David C Johnson, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
Pageof 54

Showing results (191-200 of 539) with videos related to

Sort By:
Pageof 54
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2005
Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTLCarina Lotz, Sarah Abdel Mutallib, Nicole Oehlrich, et al.
Cytometry. Part B, Clinical Cytometry|December 16, 2015
Potential therapeutic targets in plasma cell disorders: A flow cytometry studyKatharina Lisenko, Stefan Schönland, Ute Hegenbart, et al.
Cancers|July 24, 2021
Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationEva-Maria Klein, Sandra Sauer, Sabrina Klein, et al.
Transplantation and Cellular Therapy|July 2, 2021
Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma PatientsSandra Sauer, Katharina Erdmann, Alexandra D Jensen, et al.
European Journal of Haematology|December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trialFredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trialThomas Schmitt, Hartmut Goldschmidt, Kai Neben, et al.
Oncoimmunology|July 29, 2016
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitroIsabelle Krämer, Melanie Engelhardt, Sabrina Fichtner, et al.
Haematologica|October 17, 2009
Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myelomaJo Caers, Dirk Hose, Ine Kuipers, et al.
Haematologica|July 28, 2011
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patientsSophie L Corthals, Rowan Kuiper, David C Johnson, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
Pageof 54